Targets › CD83
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Apr 2028.
Transmembrane glycoprotein predominantly found on the surface of many immune cells including dendritic cells or lymphocytes that plays various roles in immune response regulation. Plays an essential role in CD4(+) T-selection, differentiation and stability by regulating the activity of the major E3 ubiquitin ligase responsible for controlling MHCII trafficking MARCHF8. (UniProt, Q01151)
Open in Phaseline: the race on CD83, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Roswell Park Cancer Institute | Autologous Anti-CD83 CAR T-cells Anti-CD83 chimeric antigen receptor (CAR) T cell therapy | CD83 | Phase 1 | Recurrent Acute Myeloid Leukemia | Apr 2028 |
Recurrent Acute Myeloid Leukemia (1)
mixed (1)
Roswell Park Cancer Institute (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.